European Pharmaceutical Pricing and Reimbursement (L23)

Venue: The Hatton

Location: London EC1N 8HN, United Kingdom

Event Date/Time: Oct 22, 2003 End Date/Time: Oct 23, 2003
Registration Date: Oct 22, 2003
Report as Spam


National pharmaceutical pricing and reimbursement is a complex and ever-changing area. In a rapidly globalising market it is essential that executives are briefed on the regulatory systems that determine the way in which your company operates and sells its products."

This event will outline the policies and fundamental principles for obtaining pharmaceutical reimbursement prices in France, Germany, Italy, Spain, and the UK. It will examine recent events and upcoming changes in pharmaceutical pricing and reimbursement, including health care regionalization in Italy and Spain.

In addition, it will reviews the impact of parallel trade and generic substitution in strategic pricing

Presentaitons will be from both the big pharma companies and the key national authorities involved.

Despite increasingly coordinated trade activities within the European Union (EU), the five major European pharmaceutical markets (France, Germany, Italy, Spain, and the UK) retain unique approaches to setting reimbursement prices on pharmaceuticals. Country-specific systems based on differing sets of authorities, negotiation processes, and fundamental principles (including pharmacoeconomics) complicate the approval of pharmaceutical prices in these countries.

Meanwhile, the ongoing evolution of health care and pharmaceutical reimbursement systems in these countries provide further challenges for a pharmaceutical company considering a European product launch. In Europe, increasing economic pressures have led to a recent rise in efforts to curtail pharmaceutical spending by national health care authorities, despite the extensive medical advances of the past few decades. While France, Italy, and Spain tightly regulate drug prices and have historically kept them at relatively low levels, this practice has resulted in a burgeoning parallel trade to higher-priced markets such as Germany and the UK. While German and British authorities encourage this trade, they are also increasingly exploring alternative mechanisms for limiting pharmaceutical expenditures, such as mandated product substitution, the use of a 'positive list' of reimbursable pharmaceuticals, and regulated price setting for generics.

Conference objectives:

Gain insight into the regulatory issues that impact pharmaceutical pricing in Europe to:

Better anticipate regulatory hurdles

Refine price approval timelines

Account for differential price windows in planning

Plan European product launches

Meet the appropriate pricing authorities directly

Expedite the price approval process in target country markets

The conference will look at policies and trends in the Five Major Markets

Overview of Pharmaceutical Pricing and Reimbursement in :

- Europe

- France

- Germany

- Italy

- Spain

- United Kingdom

The conference will give an excellent insight into the methods used to control pharmaceutical products' prices in the major European markets. It will give delegates a detailed insight into the pricing and reimbursement mechanisms in the major European markets.

Delegates will come away with a strong understanding of the key elements of pricing and reimbursement regulation. They'll gain an insight into latest policies and the political environment. And it will increase their knowledge of the ways in which governments influence and control the pharmaceutical industry.

Previous delegates and speakers include:

Glaxo SmithKline; Pfizer; Novartis; Merck & Co; Bristol-Myers Squibb; AstraZeneca; Aventis Pharmacia; Johnson & Johnson; Eli Lilly; Wyeth; Roche; Schering-Plough; Bayer; Abbott; Takeda; Boehringer Ingelheim; Sanofi-Synthelabo; Schering AG; Akzo Nobel; Sankyo; Shionogi & Company; Amgen; 3M; Yamanouchi; Nestle; Eisai; Baxter International; Merck KGaA; Novo Nordisk; Daiichi Pharmaceutical; Fujisawa; Taisho; Mitsubishi Pharma Corporation; Tyco International; Chugai; Servier; Teva; Solvay; Banyu Pharmaceutical; Tanabe Seiyaku; Elan Corporation; Genentech; Serono; Forest Laboratories; Kyowa Hakko Kogyo; Altana; Kaneka; Meiji Seika; and Allergen.

Last years speakers included:

- Dr Robert Freeman, Senior Director, Public Policy, AstraZeneca

- Anita Burrell, Director, Global Health Economics and Research of Outcomes, Aventis

- Dr Marion Bamberger, Senior Director, Economic & Government Affairs, Bristol-Myers Squibb

- Prof Fabrizio Gianfrate, Vice President & General Manager, Fondazione SmithKline

- Kate Lynch, Senior Manager, Economics & Industry Policy, Merck Sharp & Dohme

- Chris Teale, Director, Health Economics, Reimbursement & Product Access, Allergan

- Donald Macarthur, Secretary General, European Association of Euro-Pharmaceutical Companies (EAEPC)

- Kees de Joncheere, Regional Adviser Pharmaceuticals, World Health Organisation (WHO/EURO)

- Wouter Van Der Meer, Director, Strategic Change Services, PricewaterhouseCoopers

Pricing & Reimbursement in the Pharmaceutical Industry is currently in production and the full programme will be available shortly. To receive the full programme please select ‘more information’ and this will be sent to you as soon as it is completed. Delegate Bookings are being taken NOW so register your attendance TODAY to guarantee your place at this important event


The Hatton
51-53 Hatton Gardens
United Kingdom

Additional Information

Conference Price: £1099.00 Academic Discount Fee: £550.00 Details of possible additional Executive Briefing available nearer the time.